10.5281/zenodo.841216
https://zenodo.org/records/841216
oai:zenodo.org:841216
Guo, Tiannan
Tiannan
Guo
Department of Biology, Institute of Molecular Systems Biology, ETH, Zurich
Li, Li
Li
Li
CECAD, University of Cologne
Zhong, Qing
Qing
Zhong
Institute of Surgical Pathology, University Hospital Zurich
Rupp, Niels J.
Niels J.
Rupp
Institute of Surgical Pathology, University Hospital Zurich
Charmpi, Konstantina
Konstantina
Charmpi
CECAD, University of Cologne
Wong, Christine E.
Christine E.
Wong
Institute of Surgical Pathology, University Hospital Zurich
Wagner, Ulrich
Ulrich
Wagner
Institute of Surgical Pathology, University Hospital Zurich
Rueschoff, Jan H.
Jan H.
Rueschoff
Institute of Surgical Pathology, University Hospital Zurich
Jochum, Wolfram
Wolfram
Jochum
Institute of Pathology, Cantonal Hospital St. Gallen
Fankhauser, Christian
Christian
Fankhauser
Department of Urology, University Hospital Zurich
Saba, Karim
Karim
Saba
Department of Urology, University Hospital Zurich
Poyet, Cedric
Cedric
Poyet
Department of Urology, University Hospital Zurich
Wild, Peter
Peter
Wild
Institute of Surgical Pathology, University Hospital Zurich
Aebersold, Ruedi
Ruedi
Aebersold
Department of Biology, Institute of Molecular Systems Biology, ETH, Zurich / Faculty of Science, University of Zurich
Beyer, Andreas
Andreas
Beyer
CECAD, University of Cologne
Proteome heterogeneity in benign and malignant prostate tissue
Zenodo
2016
2016-09-01
Poster
10.5281/zenodo.841215
https://zenodo.org/communities/precise
https://zenodo.org/communities/eu
Creative Commons Attribution Non Commercial No Derivatives 4.0 International
Intra-tumor heterogeneity (ITH) has been characterized at the morphologic and genomic level. However, it is unclear how genomic heterogeneity is translated into functional proteome ITH. We addressed this question by performing a multi-region proteomic analysis of 60 biopsy-scale tissue samples from three prostate cancer patients using pressure cycling technology (PCT) and SWATH mass spectrometry. We quantified the degree of ITH for 1,906 proteins in malignant and benign tissue. The majority of proteins displayed a relatively low degree of ITH and benign tissue exhibited generally more complex patterns of ITH than malignant tissue. Further, we developed an ITH-corrected protein fold-change measure and demonstrated in an independent patient cohort that this new measure rescued potentially clinically relevant protein markers and stratified patients. This study established a strategy for quantifying proteome-scale ITH, generated a data resource of the proteomic ITH in prostate cancers, and demonstrated the value of considering ITH for tumor characterization.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668858. This work was supported (in part) by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0324-2. The opinions expressed and arguments employed therein do not necessarily reflect the official views of the Swiss Government.
The information in this document is provided as is, and no guarantee or warranty is given that the information is fit for any particular purpose. The content of this document reflects only the author's view - the European Commission is not responsible for any use that may be made of the information it contains. The users use the information at their sole risk and liability.
European Commission
10.13039/501100000780
668858
PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUATION